The latest price target for FibroBiologics (NASDAQ:FBLG) was reported by D. Boral Capital on November 20, 2024. The analyst firm set a price target for $16.00 expecting FBLG to rise to within 12 months (a possible 563.90% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for FibroBiologics (NASDAQ:FBLG) was provided by D. Boral Capital, and FibroBiologics maintained their buy rating.

There is no last upgrade for FibroBiologics

There is no last downgrade for FibroBiologics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of FibroBiologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for FibroBiologics was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

While ratings are subjective and will change, the latest FibroBiologics (FBLG) rating was a maintained with a price target of $16.00 to $16.00. The current price FibroBiologics (FBLG) is trading at is $2.41, which is out of the analyst’s predicted range.